NCT07117045Recruiting
Artificial Intelligence-powered Low-Dose Computed Tomography for Screening of Pancreatic Cancer
Source: ClinicalTrials.gov · Last updated 12 Aug 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with early diagnosis crucial for improving survival. Due to the absence of effective screening methods, most patients are diagnosed at advanced stages. The population undergoing low-dose computed tomography (LDCT) screening significantly overlaps with those at high risk for PDAC; however, traditional imaging methods have limited sensitivity for detecting pancreatic lesions. This study utilizes the Pancreatic Cancer Detection with Artificial Intelligence (PANDA) system to enhance LDCT for pancreatic cancer screening in a prospective, multicenter, observational cohort. PANDA will analyze LDCT images, followed by a multidisciplinary team (MDT) reassessment of abnormal interpretations. Based on MDT evaluation, individuals will be recalled for further examination, placed under a personalized follow-up plan, or monitored for at least one year. The primary outcomes include pancreatic cancer detection rate, positive predictive value, consensus rate, and recall rate, while secondary outcomes focus on early-stage cancers, resectable tumors, and safety indicators such as false positive rates and unnecessary procedures. This study aims to assess the effectiveness and safety of AI-assisted LDCT for PDAC detection, providing a practical solution for improving public health and enhancing early diagnostic capabilities.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 400000 (estimated)
- First submitted
- 5 Aug 2025
- Start date
- 15 Aug 2025
- Primary completion date
- 30 Dec 2030
- Lead sponsor
- Changhai Hospital
- Diseases
- Pancreatic cancer
- NCT number
- NCT07117045
What you commit to
- Study type: Observational
- Planned participants: 400000
- From 15 Aug 2025 to the primary completion date, 30 Dec 2030
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous history of pancreatic cancer.
- Poor image quality due to ascites, pancreatic trauma, thoracic/abdominal surgery, radiotherapy or chemotherapy.
Other
- Abdominal inflammation or diagnosis of acute pancreatitis within 6 months.
- Research subjects unable to complete follow-up due to physical or other reasons.
Who the study is looking for
- Age 50 years and above.
- Voluntary signing of informed consent.
- Completion of LDCT examination.
Age in the registry: 50 years to - · Sex: All · Accepts healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Jiaxing University Affiliated Second Hospital Coordinator of this site? Confirm its status | Jiaxing | China | Recruiting |
| Ningbo University Affiliated People's Hospital Coordinator of this site? Confirm its status | Ningbo | China | Recruiting |
| Ruici Medical Examination Institution Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
| Changhai Hospital Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
| Meinian Onehealth Healthcare Holdings Co., Ltd Coordinator of this site? Confirm its status | Shanghai | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.